课题基金 / 基金详情

Study on early diagnostic system for cervical cancer with using liquid-based cytology samples

Study on early diagnostic system for cervical cancer with using liquid-based cytology samples
液基细胞学样本宫颈癌早期诊断系统的研究
批准号:
18590319
负责人:
SANO Takaaki
金额:
$2.0万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

SANO Takaaki的其他基金

相似基金

相关文献

中文摘要
翻译
1.人乳头瘤病毒(HPV)16DNA可以整合到细胞的DNA中,从而干扰E2基因的表达,从而导致E6和E7病毒癌基因的表达增加,从而导致癌症的发生。液基细胞学标本用实时定量聚合酶链式反应进行检测。每个细胞的HPV16病毒载量从低度鳞状上皮内病变(LsIL)下降到癌性病变。3种不同HPV16型整合状态的HPV16DNA平均拷贝数分别为6 4.1、465.5和0.4。此外,单纯整合型HPV16患者的平均年龄比异型和混合型患者的平均年龄大10岁以上。结论:1.实时定量聚合酶链式反应是一种在宫颈癌筛查中对HPV进行定量和物理状态分析的有用方法。HPV L1衣壳蛋白与感染性病毒颗粒的产生同时表达,但其表达与p16表达的关系已成为宫颈HPV感染的替代标志物。用L1衣壳蛋白和p16蛋白抗体对LBC材料进行免疫化学分析。L1衣壳蛋白在30%的LSILs和12%的HSILs中呈阳性表达,而在SCC中为0。P16蛋白在55%的LSILs、100%的HSILs和100%的SCC中呈阳性表达。L1衣壳蛋白的表达随着LSILs、HSILs和SCC病变的进展而降低,而p16蛋白在所有HSILs和SCC中均为阳性。L1(-)/p16(+)病例具有进展潜能,而L1(+)/p16(-)和L1(-)/p16(-)病例可能为非进展性病变或潜在缓解期。
英文摘要
1. Human papillomavirus (HPV) 16 DNA can be integrated into the DNA of cells, thereby disrupting E2 geneexpression, which leads to increased expression of the E6 and E7 viral oncogenes and progression to cancer. Liquid-based cytology samples were examined by quantitativereal-time polymerase chain reaction. The HPV 16 viral load per cell decreased from a low-grade squamous intraepithelial lesion (LSIL) to a cancerous lesion. The average HPV 16 DNA copy numbers for three different HPV 16 integration statuses were 64.1 for the episomal form, 465.5 for the mixed form, and 0.4 for the integrated form. Furthermore, the mean age of patients with the pure integrated form of HPV 16 was more than 10 years older than those of patients with the episomal and mixed forms. Quantitative real-timePCR appears to be a useful method for quantitative and physical status analyses of HPV in cervical cancer screening with LBC samples.2. HPV L1 capsid protein is expressed together with the productionof infectious viral particles, but its expression and relation to p16 expression, which has been a surrogate marker for HPV infection in cervix. Immunochemical analyses using antibodies against L1 capsid protein and p16 protein were carried out on LBC materials. L1 capsid protein was positive in 30% of LSILs and 12% of HSILs, butin 0% of SCCs. In contrast, p16 protein was positive in 55% of LSILs, 100% of HSILs, and 100% of SCCs. Expression of L1 capsid protein decreased with lesion progression from LSILs to HSILs and SCCs, whereas p16 protein was positive in all HSILs and SCCs. The correlation between Ll and p16 expressions suggests that L1(-)/p16(+) cases have the potential for progression, whereas L1(+)/p16(-) andL1 (-)/p16(-) cases may be nonprogressive lesions or potentially in remission.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunohistochemical and molecular study on HPV infection in cervical lesions
宫颈病变中HPV感染的免疫组织化学和分子研究
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Sato K, et. al.]
通讯作者: et. al.
Study of HPV L1 capsid protein in cervical lesions
HPV L1衣壳蛋白在宫颈病变中的研究
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Yoshida T, Sano T, et. al.]
通讯作者: et. al.
Viral load and physical status of HPV type 16 in cervical lesions
宫颈病变中 HPV 16 型的病毒载量和身体状况
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Yoshida T, Sano T, et. al.]
通讯作者: et. al.
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Yoshida T, Sano T, et. al., Yoshida T, 吉田朋美 ほか]
通讯作者: 吉田朋美 ほか
共 11 条
    Study on histopathological biomarker in cervical lesions based on HPV subtypes and integration status of HPV within host genome
    • 批准号:
      22590306
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2010
    • 负责人:
      SANO Takaaki
    • 依托单位:
    Study on easy diagnostic system for cervical cancer with using p16 antibody
    • 批准号:
      16590267
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.22万
    • 财政年份:
      2004
    • 负责人:
      SANO Takaaki
    • 依托单位:
    海外基金